Everolimus Post-Bland Hepatic Artery Embolization in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis

November 12, 2026 updated by: Lowell Anthony, MD

Phase 2 Dose Optimization Trial of Everolimus Post-Bland Hepatic Artery Embolization (Evero-Embo) in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis

This study is being done to learn whether people with neuroendocrine tumors (NETs) that have spread to the liver can safely tolerate a lower dose of everolimus after bland hepatic artery embolization (HAE).

Study Overview

Study Type

Interventional

Enrollment (Estimated)

12

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Lowell B Anthony, MD
  • Phone Number: 859-257-4488
  • Email: lan225@uky.edu

Study Locations

    • Kentucky
      • Lexington, Kentucky, United States, 40536
        • University of Kentucky
        • Contact:
          • Lowell B Anthony, MD
          • Phone Number: 859-257-4488
          • Email: lan225@uky.edu
        • Principal Investigator:
          • Lowell B Anthony, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed Grade 1 or 2 NET with measurable liver metastasis (≥1.0 cm).
  • Morphologically progressive disease by RECIST 1.1 and/or ≥25% but ≤75% tumor burden in the liver.
  • Prior tolerance of at least 5 mg daily everolimus for ≥5 days pre-HAE. NOTE: There is no maximum amount of time a patient may be taking Everolimus before HAE as the study focuses on after the pre-HAE dose is established.
  • Prior therapy: Patients are eligible regardless of the number or type of prior therapies and without a requirement to have received a specific therapy prior to enrollment. Patients will take everolimus leading up to the embolization once enrolled in the study. They will only be enrolled in the study for their first hepatic artery embolization. They must be 30 days out since their last cancer treatment of any kind, not including somatostatin analogs.
  • Age ≥18 years.
  • ECOG performance status ≤2 (see Appendix A).
  • Patients must have adequate organ and marrow function as defined below:
  • absolute neutrophil count ≥1,000/mcL
  • platelets ≥100,000/mcL
  • total bilirubin ≤ institutional upper limit of normal (ULN)
  • Child-Turcotte-Pugh class A; B dose reduction is recommended at 5mg QD or less; C recommend non-usage of everolimus
  • Creatinine (or GFR) ≤ institutional ULN (Appendix B)
  • GFR, glomerular filtration rate (or creatinine) There are no dose reductions required for patients in any stage of renal failure for everolimus
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Patients with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.
  • Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion Criteria:

  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.
  • Prior transhepatic artery embolization.
  • Contraindication to arteriography or embolization.
  • Prior chemotherapy or peptide receptor radionuclide therapy within 1 month.
  • Biliary stent or choledocho-enteric anastomosis.
  • Patients who are receiving any other investigational agents for the treatment of this cancer.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus
  • Concomitant medications: Patients should only be excluded from trial participation when clinically relevant known or predicted drug-drug interactions or potential overlapping toxicities will impact safety or efficacy. Drug-drug interactions of risk level X will be excluded from the trial unless an alternative medication can be substituted. Drug-drug interactions are classified into classes A, B, C, D and X. A Class X drug interaction represents a high-risk, contraindicated combination where the risks of taking the medications together clearly outweigh any potential benefits. These medications include Antihepaciviral Combination Products, BCG Products, Brivudine, Chikungunya Vaccine (Live), Chloramphenicol (Systemic), Cladribine, Dengue Tetravalent Vaccine (Live), Etrasimod, Fexinidazole, Grapefruit Juice, Inhibitors of CYP3A4 (Strong) and P-glycoprotein, Mumps- Rubella- or Varicella-Containing Live Vaccines, Nadofaragene Firadenovec, Natalizumab, Pimecrolimus, Pimozide, Poliovirus Vaccines (Live/Oral), Tacrolimus (Topical), Talimogene Laherparepvec, Tertomotide, Thiamphenicol, Typhoid Vaccine, Vaccines (Live), Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated). Additionally, patients should avoid taking everolimus while on strong CYP3A4 inhibitors. They should have everolimus dose reduction to 2.5 mg PO while on moderate CYP34A inhibitors and/or PgP inhibitors. An increase in everolimus dose is recommended when co-administered with a strong CYP3A4 inducer (see package insert, Appendix C).
  • Patients with uncontrolled intercurrent illness.
  • Pregnant women are excluded from this study because everolimus is an mTOR inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with everolimus, breastfeeding should be discontinued if the mother is treated with everolimus. NOTE: Patients treated with everolimus should use highly effective birth control during treatment and for 8 weeks after their last everolimus dosing. Male patients with female partners of reproductive potential should be advised to use effective contraception during treatment with everolimus and for 4 weeks after the last dose

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Everolimus following Bland Hepatic Artery Embolization

Everolimus 5mg will be provided orally for 7 days pre embolization then every other day beginning day 2 through day 30, post embolization. Bland Hepatic Artery procedure will occur on Day 0.

Everolimus 5mg will be provided orally for 7 days pre embolization then every other day beginning day 2 through day 30, post embolization

Bland Hepatic Artery Embolization (HAE) will occur on Day 0.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of patients who can tolerate everolimus pre and post HAE
Time Frame: Pre-study to Day 30

To assess the percentage of patients who can tolerate ½ pre-embolization everolimus dose administered every other day post-bland hepatic artery embolization of liver metastasis in neuroendocrine tumor (NET) patients (dose optimization trial).

Pre-study to Day 30

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective Response Rate
Time Frame: Pre-study to Day 30

To determine the objective response rate (ORR) and hepatic progression-free survival (hPFS).

Pre-study to Day 30
Progression Free Survival
Time Frame: Pre-study to Day 30

To determine the objective response rate (ORR) and hepatic progression-free survival

Pre-study to Day 30
Biochemical Response
Time Frame: Pre-study to Day 30

To evaluate biochemical response using Chromogranin A (CGA), serotonin, and 5-HIAA levels, defined as a 50% reduction from baseline if elevated.

Pre-study to Day 30

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lowell B Anthony, MD, University of Kentucky

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 16, 2026

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

July 1, 2029

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe